Hetrick Brian, Yu Dongyang, Olanrewaju Adeyemi A, Chilin Linda D, He Sijia, Dabbagh Deemah, Alluhaibi Ghaliah, Ma Yuan-Chun, Hofmann Lewis A, Hakami Ramin M, Wu Yuntao
National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, Manassas, VA, 20110, USA.
Virongy LLC, Manassas, VA, 20109, USA.
Cell Biosci. 2021 May 29;11(1):100. doi: 10.1186/s13578-021-00609-1.
The ongoing global pandemic of coronavirus disease 2019 (COVID-19) has resulted in the infection of over 128 million people and has caused over 2.8 million deaths as of April 2021 in more than 220 countries and territories. Currently, there is no effective treatment for COVID-19 to reduce mortality. We investigated the potential anti-coronavirus activities from an oral liquid of traditional medicine, Respiratory Detox Shot (RDS), which contains mostly herbal ingredients traditionally used to manage lung diseases.
Here we report that RDS inhibited the infection of target cells by lenti-SARS-CoV, lenti-SARS-CoV-2, and hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) pseudoviruses, and by infectious SARS-CoV-2 and derived Ha-CoV-2 variants including B.1.1.7, B.1.351, P.1, B.1.429, B.1.2, B.1.494, B.1.1.207, B.1.258, and B.1.1.298. We further demonstrated that RDS directly inactivates the infectivity of SARS-CoV-2 virus particles. In addition, we found that RDS can also block the infection of target cells by Influenza A virus.
These results suggest that RDS may broadly inhibit the infection of respiratory viruses.
截至2021年4月,正在全球范围内肆虐的2019冠状病毒病(COVID-19)已导致超过1.28亿人感染,在220多个国家和地区造成了超过280万人死亡。目前,尚无有效的COVID-19治疗方法可降低死亡率。我们研究了一种传统中药口服液——呼吸道排毒液(RDS)的潜在抗冠状病毒活性,该口服液主要含有传统上用于治疗肺部疾病的草药成分。
我们在此报告,RDS可抑制慢病毒 - 严重急性呼吸综合征冠状病毒(lenti - SARS-CoV)、慢病毒 - 严重急性呼吸综合征冠状病毒2(lenti - SARS-CoV-2)以及杂交甲病毒 - 严重急性呼吸综合征冠状病毒2(Ha-CoV-2)假病毒对靶细胞的感染,还可抑制传染性严重急性呼吸综合征冠状病毒2及其衍生的Ha-CoV-2变体(包括B.1.1.7、B.1.351、P.1、B.1.429、B.1.2、B.1.494、B.1.1.207、B.1.258和B.1.1.298)对靶细胞的感染。我们进一步证明,RDS可直接使严重急性呼吸综合征冠状病毒2病毒颗粒的感染性失活。此外,我们发现RDS还可阻断甲型流感病毒对靶细胞的感染。
这些结果表明,RDS可能广泛抑制呼吸道病毒的感染。